DNA damage by mycotoxins

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 424, Issue 1-2, 1999, Pages 167-181

  Wang, Jia Sheng ^a   Groopman, John D ^a  

^a The Johns Hopkins University   (United States)

Author keywords

Aflatoxin; Aflatoxin B1 N7 guanine adduct; DNA damage; Human hepatocellular carcinoma; Mycotoxin

Indexed keywords

AFLATOXIN; AFLATOXIN B1; MYCOTOXIN; OCHRATOXIN; STERIGMATOCYSTIN; ZEARALENONE;

CARCINOGENESIS; DNA ADDUCT; DNA DAMAGE; HUMAN; LIVER CELL CARCINOMA; MOUSE; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; URINARY EXCRETION;

ANIMALIA; PENICILLIUM; RODENTIA; SALMONIDAE;

EID: 0033535416     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(99)00017-2     Document Type: Article

References (91)

1. R.P. Sharma, D.K. Salunkhe (Eds.), Mycotoxins and Phytotoxins, CRC Press, Boca Raton, FL, 1991.
2. J.D. Miller, H.L. Trenholm (Eds.), Mycotoxins in Grain: Compounds Other Than Aflatoxins, Eagan Press, St. Paul, MN, 1994.
3. J.M. Beardall, J.D. Miller, Diseases in humans with mycotoxins as possible causes, in: J.D. Miller, H.L. Trenholm (Eds.), Mycotoxins in Grain: Compounds Other Than Aflatoxins, Eagan Press, St. Paul, MN, 1994, pp. 487-539.
4. W.F. Busby, Jr., G.N. Wogan, Aflatoxins, in: C.E. Searle (Ed.), Chemical Carcinogens, 2nd edn., American Chemical Society, Washington, DC, 1985, pp. 945-1136.
5. Ueno Y., Kubota K. DNA-attacking ability of carcinogenic mycotoxins in recombination-deficient mutant cells of Bacillus subtilus. Cancer Res. 36:1976;445-451.
6. Council for Agricultural Sciences and Technology, Mycotoxins: Economic and Health Risks, Report No. 116, Ames, IA, 1989, pp. 1-70.
7. W.C.A. Gelderblom, S.D. Snyman, S. Abel, S. Lebepe-Mazur, C.M. Smuts, L. Van der Westhuizen, W.F.O. Marasas, T.C. Victor, S. Knasmuller, W. Huber, Hepatotoxicity and carcinogenicity of the fumonisins in rats: a review regarding mechanistic implications for establishing risk in humans, in: L.S. Jackson, J.W. DeVries, L.B. Bullerman (Eds.), Fumonisins in Food, Advances in Experimental Medicine and Biology, Vol. 392, Plenum, New York, 1995, pp. 279-296.
8. International Agency for Research on Cancer Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. IARC Monogr. Eval. Carcinog. Risks Hum. 56:1993;245-540.
9. D.L. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins, Human Health, Veterinary, and Agricultural Significance, Academic Press, San Diego, 1994.
10. McConnell I.R., Garner R.C. DNA adducts of aflatoxins, sterigmatocystin and other mycotoxins. IARC Sci. Publ. 125:1994;49-55.
11. 1 and its implications to quantitative cancer-risk assessment. Mutat. Res. 296:1993;181-198.
12. 1 carcinogenesis in rats. Cancer Res. 27:1967;2370-2376.
13. McLean M., Dutton M.F. Cellular interactions and metabolism of aflatoxin: an update. Pharmacol. Ther. 65:1995;163-192.
14. McCann J., Choi E., Yamasaki E., Ames B.N. Detection of carcinogens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci. USA. 72:1975;5135-5139.
15. 1. Proc. Natl. Acad. Sci. USA. 80:1983;2695-2698.
16. 1 in vitro. Proc. Natl. Acad. Sci. USA. 74:1977;1870-1874.
17. 1-DNA adduct formed in vivo in rat liver. Proc. Natl. Acad. Sci. USA. 75:1978;1745-1749.
18. 1. Cancer Res. 41:1981;197-203.
19. AFBGCAT) Biochemistry. 29:1990;10438-10448.
20. Johnson W.W., Guengerich F.P. Reaction of AFB1 exo-8,9-epoxide with DNA: kinetic analysis of covalent binding and DNA-induced hydrolysis. Proc. Natl. Acad. Sci. USA. 94:1997;6121-6125.
21. 1 adducts in a p53 mutational hotspot. Proc. Natl. Acad. Sci. USA. 94:1997;9579-9584.
22. 1 creates alkali-labile lesions in DNA at positions of guanine and adenine. Proc. Natl. Acad. Sci. USA. 75:1978;4120-4124.
23. 1-dichloride to cytosine in DNA. Carcinogenesis. 12:1991;997-1002.
24. 1-induced 8-hydroxy-deoxyguanosine formation in rat hepatic DNA. Carcinogenesis. 16:1995;419-422.
25. 1-treated rat liver and human oral mucosal cells. Cancer Res. 56:1996;683-688.
26. Croy R.G., Wogan G.N. Quantitative comparison of covalent aflatoxin-DNA adducts formed in rat and mouse livers and kidneys. J. Natl. Cancer Inst. 66:1981;761-768.
27. 1 carcinogenesis and its relation to DNA adduct formation and adduct persistence in sensitive and resistant salmonid fish. Carcinogenesis. 9:1988;1919-1926.
28. 1 in rats at very low exposure. Cancer Res. 42:1982;3659-3662.
29. 1. Carcinogenesis. 11:1990;2133-2135.
30. G.S. Bailey, Role of aflatoxin-DNA adducts in the cancer process, in: D.L. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance, Academic Press, San Diego, 1994, pp. 137-148.
31. 1, in: D.L. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance, Academic Press, San Diego, 1994, pp. 89-101.
32. 1-DNA adducts: linear correlation with hepatic cancer risk. Regul. Toxicol. Pharmacol. 10:1989;74-81.
33. 1-treated rats. Cancer Res. 41:1981;650-654.
34. 7-guanine and other aflatoxin metabolites by multiple monoclonal antibody affinity chromatography and HPLC. Cancer Res. 52:1992;267-274.
35. 1 in human urine collected in Murang'a district, Kenya. Carcinogenesis. 4:1983;1193-1195.
36. 1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res. 47:1987;3430-3433.
37. Groopman J.D., Zhu J., Donahue P.R., Pikul A., Zhang L.-S., Chen J.-S., Wogan G.N. Molecular dosimetry of urinary aflatoxin DNA adducts in people living in Guangxi Autonomous Region, People's Republic of China. Cancer Res. 52:1992;45-51.
38. 7-guanine in human urine obtained in The Gambia, West Africa. Cancer Epidemiol. Biomarkers & Prev. 1:1992;221-228.
39. 1-DNA adducts. Cancer Epidemiol. Biomarkers & Prev. 5:1996;613-619.
40. 1-DNA adducts in healthy males. Carcinogenesis. 18:1997;1189-1194.
41. 7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res. 46:1986;3924-3931.
42. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res. 51:1991;5501-5506.
43. Groopman J.D., Egner P., Love-Hunt A., DeMatos P., Kensler T.W. Molecular dosimetry of aflatoxin DNA and serum albumin adducts in chemoprotection studies using 1,2-dithiol-3-thione in rats. Carcinogenesis. 13:1992;101-106.
44. Kensler T.W., Groopman J.D., Eaton D.L., Curphey T.J., Roebuck B.D. Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional inducer 1,2-dithiol-3-thione. Carcinogenesis. 13:1992;95-100.
45. E.L. Loechler, Mechanisms by which aflatoxins and other bulky carcinogens induce mutations, in: D.L. Eaton, J.D. Groopman (Eds.), The Toxicology of Aflatoxins: Human Health, Veterinary, and Agricultural Significance, Academic Press, San Diego, 1994, pp. 149-178.
46. 1-DNA adducts by the UvrABC endonuclease of Escherichia coli. J. Biol. Chem. 268:1993;7990-8002.
47. Harris C.C., Wang X., Forrester K., Felley-Bosco E., Bennett W.P., DeBenedetti V., Hollstein M. Molecular carcinogenesis to molecular epidemiology. Proc. Am. Assoc. Cancer Res. 34:1993;614-615.
48. Wang J.-S., Busby W.F. Jr., Wogan G.N. Formation and persistence of DNA adducts in organs of CD-1 mice treated with a tumorigenic dose of fluoranthene. Carcinogenesis. 16:1995;2609-2616.
49. 1-DNA adducts and hepatitis B virus antigens in hepatocellular carcinoma and non-tumorous liver tissue. Environ. Health Perspect. 99:1993;199-202.
50. D.P.H. Hsieh, Genotoxicity of mycotoxins, in: P.L. Chambers, P. Gebring, F. Sakai (Eds.), New Concepts and Developments in Toxicology, Elsevier, New York, 1986, pp. 251-259.
51. 1-induced mutations in a plasmid replicated in xeroderma pigmentosum and DNA repair proficient human cells. Cancer Res. 52:1992;5668-5673.
52. 1-DNA adduct. Proc. Natl. Acad. Sci. USA. 93:1996;1535-1539.
53. 1-induced hepatocellular carcinomas. Biochem. Biophys. Res. Commun. 138:1986;858-864.
54. 1. Proc. Natl. Acad. Sci. USA. 83:1986;9418-9422.
55. Sinha S., Webber C., Marshall C.J., Knowles M.A., Procter A., Barrass N.C., Neal G.E. Activation of ras oncogene in aflatoxin-induced rat liver carcinogenesis. Proc. Natl. Acad. Sci. USA. 85:1988;3673-3677.
56. 1-induced hepatocellular carcinoma and adenoma in the rat: detection by denaturing gradient gel electrophoresis. Proc. Natl. Acad. Sci. USA. 90:1993;2045-3049.
57. 1-induced rat liver tumors. Proc. Natl. Acad. Sci. USA. 87:1990;1104-1108.
58. Bauer-Hofmann R., Buchmann A., Wright A.S., Schwarz M. Mutations in the Ha-ras protooncogene in spontaneous and chemically induced liver tumors of the CF1 mouse. Carcinogenesis. 11:1990;1875-1877.
59. Wiseman R., Stowers S., Miller E., Anderson M., Miller J. Activating mutations of the c-Ha-ras protooncogene in chemically induced hepatomas of the male B63F1 mouse. Proc. Natl. Acad. Sci. USA. 83:1986;5825-5829.
60. 1. Carcinogenesis. 18:1997;905-910.
61. National Cancer Office of the Ministry of Public Health, PRC, Studies on Mortality Rates of Cancer in China, People's Publishing House, Beijing, PRC, 1980.
62. Groopman J.D., Cain L.G., Kensler T.W. Aflatoxin exposure in human populations and relationship to cancer. Crit. Rev. Toxicol. 19:1988;113-145.
63. Groopman J.D., Wang J.-S., Scholl P.F. Molecular biomarkers for aflatoxins: from adducts to gene mutations to human liver cancer. Can. J. Physiol. Pharmacol. 74:1996;203-209.
64. Wang L., Hatch M., Chen C., Levin B., You S., Lu S., Wu M., Wu W.P., Wang L.W., Wang Q., Huang G., Yang P., Lee H., Santella R.M. Aflatoxin exposure and risk of hepatocarcinoma in Taiwan. Int. J. Cancer. 67:1996;602-625.
65. Wogan G.N. Aflatoxins as risk factors for hepatocellular carcinoma in humans. Cancer Res. 52:1992;2114s-2118s.
66. Campbell T.C., Chen J.S., Liu C.B., Li J.Y., Parpia B. Non-association of aflatoxin with primary liver cancer in a cross-sectional ecological survey in the People's Republic of China. Cancer Res. 50:1990;6882-6893.
67. Srivatanakul P., Parkin D.M., Jiang Y.Z., Khlat M., Kao-Ian U.T., Sontipong S., Wild C.P. The role of infection by Opisthorchis viverrini, hepatitis B virus, and aflatoxin exposure in the etiology of liver cancer in Thailand, a correlation study. Cancer. 68:1991;2411-2417.
68. Yeh F.-S., Shen K.-N. Epidemiology and early diagnosis of primary liver cancer in China. Adv. Cancer Res. 47:1986;297-329.
69. Yeh F.-S., Yu M.C., Mo C., Luo S., Tong M.J., Henderson B.E. Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. Cancer Res. 49:1989;2506-2509.
70. Qian G.-S., Yu M.C., Ross R., Yuan J.-M., Gao Y.-T., Wogan G.N., Groopman J.D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, PRC. Cancer Epidemiol. Biomarkers Prev. 3:1994;3-11.
71. Ross R., Yuan J.-M., Yu M.C., Wogan G.N., Qian G.-S., Tu J.-T., Groopman J.D., Gao Y.-T., Henderson B.E. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet. 339:1992;943-946.
72. Kuang S.-Y., Fang X., Lu B.-X., Zhang Q.-N., Wu Y., Wang J.-B., Zhu Y.-R., Groopman J.D., Kensler T.W., Qian G.-S. Aflatoxin-albumin adducts and risk for hepatocellular carcinoma in residents of Qidong, People's Republic of China. Proc. Am. Assoc. Cancer Res. 37:1996;1714.
73. Lunn R.M., Zhang Y.-J., Wang L.-Y., Chen C.-J., Lee P.-H., Lee C.-S., Tsai W.-Y., Santella R.M. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res. 57:1997;3471-3477.
74. 1 adduct level and risk of hepatocellular carcinoma. Proc. Am. Assoc. Cancer Res. 36:1995;1644.
75. Yu M.-W., Lien J.-P., Chiu Y.H., Santella R.M., Liaw Y.F., Chen C.J. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J. Hepatol. 27:1997;320-330.
76. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from Southern Africa. Nature. 350:1991;429-431.
77. Hsu I.C., Metcalf R.A., Sun T., Wesh J.A., Wang N.J., Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 350:1991;427-428.
78. Li D., Gao Y., He L., Wang N.J., Gu J. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis. 14:1993;169-173.
79. Ozturk M.et al. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet. 338:1991;1356-1359.
80. Fujimoto Y., Hampton L.L., Wirth P.J., Wang N.J., Xie J.P., Thorgeirsson S.S. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinoma in China. Cancer Res. 54:1994;281-285.
81. Coursaget P., Depril N., Chabaud M., Nandi R., Mayelo V., LeCann P., Yvonnet B. High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br. J. Cancer. 67:1993;1395-1397.
82. Aguilar F., Harris C.C., Sun T., Hollstein M., Cerutti P. Geographic variation of p53 mutational profile in non-malignant human liver. Science. 264:1994;1317-1319.
83. Puisieux A., Lim S., Groopman J.D., Ozturk M. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res. 51:1991;6185-6189.
84. 1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA. 90:1993;8586-8590.
85. Cerutti P., Hussain P., Pourzand C., Aguilar F. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res. 54:1994;1934s-1938s.
86. Kuiper-Goodman T., Scott P.M. Risk assessment of the mycotoxin ochratoxin A. Biomed. Environ. Sci. 2:1989;179-248.
87. A. Pfohl-Leszkowicz, A.K. Chakor, E.E. Creppy, G. Dirheimer, DNA adduct formation in mice treated with ochratoxin A, in: M. Castegnaro, R. Plestina, G. Dirheimer, I.V. Chernozemsky, H. Bartsch (Eds.), Mycotoxin, Endemic Nephropathy and Urinary Tract Tumors, IARC Sci. Publ. No. 115, International Agency for Research on Cancer, Lyon, 1991, pp. 245-253.
88. Pfohl-Leszkowicz A., Grosse Y., Kane A., Creppy E.E., Dirheimer G. Differential DNA adduct formation and disappearance in three mouse tissues after treatment with the mycotoxin ochratoxin A. Mutat. Res. 289:1993;265-273.
89. Kuiper-Goodman T., Scott P.M., Watanabe H. Risk assessment of the mycotoxin zearalenone. Regul. Toxicol. Pharmacol. 7:1987;253-306.
90. D.B. Prelusky, B.A. Rotter, R.G. Rotter, Toxicology of mycotoxins, in: J.D. Miller, H.L. Trenholm (Eds.), Mycotoxins in Grain: Compounds Other Than Aflatoxins, Eagan Press, St. Paul, MN, 1994, pp. 359-403.
91. Pfohl-Leszkowicz A., Chekir-Ghedira L., Bacha H. Genotoxicity of zearalenone, an estrogenic mycotoxin: DNA adduct formation in female mouse tissues. Carcinogenesis. 16:1995;2315-2320.